Investors seeking exposure to the tech sector could adopt a diversified approach to investing in sub-segments that have a reasonably good earning visibility and structural strength of the business.
A stock may be sold from the portfolio when it is fully valued, if additional information from the research group gives reason to expect a negative shift in fundamentals, or if the earnings revision trend turns negative. If a stock has under-performed, we may decide to sell the position if there is a reason to believe that the factors driving the correction are long term in nature.
The decision to sell a stock is triggered by 5 events:
- Negative earnings surprise
- Adverse policy changes
- Stock becoming expensive on valuation parameters
- Relative attractiveness
- Trading calls
Export oriented sectors continue to face demand headwinds. The global generics within pharmaceutical sector continue to remain challenged on account of pricing pressures and increasing complexity of product development. Technology sector is also going through short term demand uncertainty. However, the current expectations about US economic growth hints at soft-landing rather than recession. So, we believe that the uncertainty engulfing domestic IT sector shouldn't be prolonged.
A key challenge was to deal with pockets of high valuation in mid & small caps segment. The risk of exposure to high valuation businesses called for adopting a cautious approach. Buy and hold strategy followed in our equity portfolios helped us. Many of the Key stocks that caused underperformance in FY2022 rebounded in FY2023. Looking past the near-term underperformance, conviction in the underlying business worked favourably for the portfolio as markets recognized value in these holdings.